ARGX Key Statistics, Chart & Performance
The current stock price of ARGX is 795.57 USD. In the past month the price decreased by -10.55%. In the past year, price increased by 21.23%.
ARGX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.72 | 396.12B | ||
| AMGN | AMGEN INC | 15.09 | 177.76B | ||
| GILD | GILEAD SCIENCES INC | 14.73 | 149.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.06 | 119.17B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.8 | 84.19B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 783.14 | 52.76B | ||
| INSM | INSMED INC | N/A | 36.31B | ||
| NTRA | NATERA INC | N/A | 33.06B | ||
| BIIB | BIOGEN INC | 11.11 | 27.29B | ||
| INCY | INCYTE CORP | 16.5 | 20.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.6 | 21.14B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 20.76B |
Related stock screener links
About ARGX
Company Profile
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland and currently employs 1,599 full-time employees. The company went IPO on 2014-07-10. The company is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
Company Info
ARGENX SE - ADR
Laarderhoogtweg 25
Amsterdam NOORD-HOLLAND 4811 AH NL
CEO: Tim Van Hauwermeiren
Employees: 1599
Phone: 31763030
ARGENX SE - ADR / ARGX FAQ
What does ARGX do?
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland and currently employs 1,599 full-time employees. The company went IPO on 2014-07-10. The company is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
What is the current price of ARGX stock?
The current stock price of ARGX is 795.57 USD. The price decreased by -3.33% in the last trading session.
What is the dividend status of ARGENX SE - ADR?
ARGX does not pay a dividend.
What is the ChartMill rating of ARGENX SE - ADR stock?
ARGX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What is the analyst forecast for ARGX stock?
25 analysts have analysed ARGX and the average price target is 972.7 USD. This implies a price increase of 22.26% is expected in the next year compared to the current price of 795.57.
How is the valuation of ARGENX SE - ADR (ARGX) based on its PE ratio?
The PE ratio for ARGENX SE - ADR (ARGX) is 59.33. This is based on the reported non-GAAP earnings per share of 13.41 and the current share price of 795.57 USD.
Can you provide the market cap for ARGENX SE - ADR?
ARGENX SE - ADR (ARGX) has a market capitalization of 48.98B USD. This makes ARGX a Large Cap stock.
ARGX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ARGX. When comparing the yearly performance of all stocks, ARGX turns out to be only a medium performer in the overall market: it outperformed 63.67% of all stocks.
ARGX Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to ARGX. ARGX has an excellent financial health rating, but there are some minor concerns on its profitability.
ARGX Financial Highlights
Over the last trailing twelve months ARGX reported a non-GAAP Earnings per Share(EPS) of 13.41. The EPS increased by 1512.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 41.97% | ||
| ROA | 17.84% | ||
| ROE | 21% | ||
| Debt/Equity | 0.01 |
ARGX Forecast & Estimates
25 analysts have analysed ARGX and the average price target is 972.7 USD. This implies a price increase of 22.26% is expected in the next year compared to the current price of 795.57.
For the next year, analysts expect an EPS growth of 935.48% and a revenue growth 95.19% for ARGX